In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Centocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.

You may also be interested in...

Lung Cancer Nucleic Acid Test Clinicals Under Development By DiagnoCure

DiagnoCure says its R&D collaboration with Compugen Ltd. will spur the launch of pivotal clinical studies evaluating a nucleic acid-based test for lung cancer by mid-2003

Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts